Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Appendix B: Panel Roster and Financial Disclosures

Candida

Last Updated: August 1, 2019; Last Reviewed: August 1, 2019

Mucocutaneous Candidiasis
Member Financial Disclosure
Company Relationship
Lionakis, Michail* National Institutes of Health None N/A
Mansour, Michael Massachusetts General Hospital Celularity Advisory Board
GenMark Diagnostics Advisory Board
National Institutes of Health Research Support
SmartPharm Consultant
UpToDate Medical Writing
Vericel Consultant
Nett, Jeniel University of Washington Madison Burroughs Wellcome Fund Research Support
Doris Duke Charitable Foundation Research Support
National Institutes of Health Research Support
Ostrosky-Zeichner, Luis University of Texas Houston Astellas Advisory Board, Consultant, Research Support
Amplyx Research Support
Cidara Advisory Board, Research Support
FZG Advisory Board
Mayne Advisory Board
Merck Speaker’s Bureau
Pfizer Speaker’s Bureau
SCYNEXIS, Inc Research Support
Revankar, Sanjay
Wayne State University School of Medicine Astellas Research Support
Sobel, Jack Wayne State University School of Medicine SCYNEXIS, Inc Advisory Board
UpToDate Medical Writing

* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines